Blueshift Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Blueshift Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,792	Closed	-$593K	–	458
2025 Q2	$593K	Buy	+10,792	New	+$635K	0.18%	149
2025 Q1	–	Sell	-5,314	Closed	-$349K	–	405
2024 Q4	$349K	Buy	+5,314	New	+$356K	0.13%	223
2022 Q4	–	Sell	-2,523	Closed	-$214K	–	372
2022 Q3	$214K	Buy	+2,523	New	+$225K	0.05%	496
2022 Q2	–	Sell	-8,243	Closed	-$636K	–	700
2022 Q1	$636K	Buy	+8,243	New	+$690K	0.06%	365
2021 Q2	–	Sell	-10,455	Closed	-$789K	–	930
2021 Q1	$789K	Buy	+10,455	New	+$854K	0.08%	331

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Blueshift Asset Management's BMRN Position: Q3 2025 in Review

Blueshift Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 10,792 shares — an estimated $593K sold.

Blueshift Asset Management first reported a position in BMRN in Q1 2021 and held it in 5 quarters. The position peaked at $789K in Q1 2021. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

Blueshift Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Blueshift Asset Management sold 10,792 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $593K.
Blueshift Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Blueshift Asset Management's BioMarin Pharmaceuticals position peaked at $789K in Q1 2021.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Blueshift Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.